Amlodipine/valsartan
 |
|
 |
|
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Valsartan | Angiotensin II receptor antagonist |
| Clinical data | |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 1190398-97-0 |
| ATC code | C09DB01 (WHO) |
| PubChem | CID: 11354874 |
| ChemSpider | 13092186  |
| KEGG | D09745 |
| (verify) | |
Amlodipine/valsartan is of an oral blood pressure lowering combination drug which combines two medications in a film-coated tablet. It contains amlodipine, a dihydropyridine-type calcium channel blocker,[1] and valsartan, an angiotensin II receptor antagonist (ARB or A2RA); typically formulated as the benzenesulfonate salt. Meta-analysis has shown this combination to be well tolerated and effective for the reduction of blood pressure.[2]
The combination was originally patented by Novartis Pharmaceuticals under the brand name Exforge. The patent expired in September 2012.[3]
Amlodipine/valsartan is available in different dose preparations: 5 mg/80 mg, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10/320 mg of amlodipine and valsartan, respectively.
The combination is also available with included hydrochlorothiazide, for patients who need a three drug regimen to manage their blood pressure.
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
